'''Pexelizumab''' is a [[pharmaceutical drug|drug]] designed to reduce side effects of [[coronary artery bypass grafting]]<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00088179 ClinicalTrials.gov:] Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass</ref> and [[angioplasty]],<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00091637 ClinicalTrials.gov:] Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction</ref><ref>{{cite journal|pmid=18954626|year=2008|last1=Testa|first1=L|last2=Van Gaal|last3=Bhindi|last4=Biondi-Zoccai|last5=Abbate|last6=Agostoni|last7=Porto|last8=Andreotti|last9=Crea|title=Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients|volume=136|issue=4|pages=884–93|doi=10.1016/j.jtcvs.2007.12.062|journal=The Journal of thoracic and cardiovascular surgery|first2=WJ|first3=R|first4=GG|first5=A|first6=P|first7=I|first8=F|first9=F|last10=Banning|first10=A.P.|display-authors=8}}</ref> among other types of [[cardiac surgery]]. It is a [[single chain variable fragment]] of a [[monoclonal antibody]] targeted against [[Complement component 5|component 5]] of the [[complement system]].<ref>{{cite journal|pmid=15331798|year=2004|last1=Mathew|first1=JP|last2=Shernan|first2=SK|last3=White|first3=WD|last4=Fitch|first4=JC|last5=Chen|first5=JC|last6=Bell|first6=L|last7=Newman|first7=MF|title=Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.|volume=35|issue=10|pages=2335–9|doi=10.1161/01.STR.0000141938.00524.83|journal=Stroke; a journal of cerebral circulation}}</ref>
